

|   |   |  |                    |                  |
|---|---|--|--------------------|------------------|
| Patient ID<br><b>SA00140358</b>                       | Patient Name<br><b>VALIDATIONSFT, TESTING G6PD1</b> | Birth Date<br><b>2000-01-01</b>            | Gender<br><b>M</b> | Age<br><b>20</b> |
| Order Number<br><b>SA00140358</b>                     | Client Order Number<br><b>SA00140358</b>            | Ordering Physician<br><b>CLIENT,CLIENT</b> | Report Notes       |                  |
| Account Information<br><b>C7028846 DLMP Rochester</b> |   | Collected<br><b>17 Nov 2020 06:00</b>      |                    |                  |

## G6PD Enzyme Activity, B

| Result Name  | Value | Unit   | Reference Value | Performing Site |
|--|-------|--------|-----------------|-----------------|
| G6PD Enzyme Activity, B  | 9.7   | U/g Hb | 8.0–11.9        | <b>1</b> MCR    |
| Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency is classified according to WHO criteria based on enzyme activity level but accurate classification requires correlation with clinical and possibly genetic data. Enzyme levels less than 10% of mean normal are found in WHO class I (chronic) and class II (episodic) variants. Levels between 10 and 60% can be seen in class III (episodic) variants or female carrier states and genotyping can be useful in this range. Levels greater than 60% are considered sufficient and are seen in normal persons, female carrier states, or G6PD variants with subclinical effect (WHO class IV). Note: G6PD deficiency can be masked in the setting of reticulocytosis, markedly elevated WBCs or recent transfusion. If any of these are present in the setting of neonatal, chronic or episodic jaundice/anemia, genotyping is recommended. If desired, please order Glucose-6-Phosphate Dehydrogenase (G6PD) Full Gene Sequencing (test G6PDB). |       |        |                 |                 |

**Received:** 17 Nov 2020 11:48

**Reported:** 17 Nov 2020 11:50

### Laboratory Notes

- 1** This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

### Performing Site Legend

| Code | Laboratory                                       | Address                                  | Lab Director                | CLIA Certificate |
|------|--|--|-----------------------------|------------------|
| MCR  | Mayo Clinic Laboratories - Rochester Main Campus | 200 First Street SW, Rochester, MN 55905 | William G. Morice M.D. Ph.D | 24D0404292       |